Daxor (DXR) 3-Year Dividend Growth Rate

: 0.00% (As of Dec. 2023)

View and export this data going back to 1992. Start your Free Trial

Daxor's Dividends per Share for the six months ended in Dec. 2023 was $0.00.

The historical rank and industry rank for Daxor's 3-Year Dividend Growth Rate or its related term are showing as below:

During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Daxor was -15.70% per year. The lowest was -68.90% per year. And the median was -45.70% per year.

DXR's 3-Year Dividend Growth Rate is not ranked ^*
in the Medical Devices & Instruments industry.
Industry Median: 11.9
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Daxor's Dividend Payout Ratio for the six months ended in Dec. 2023 was 0.00. As of today, Daxor's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison

For the Medical Instruments & Supplies subindustry, Daxor's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Daxor 3-Year Dividend Growth Rate Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Daxor's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Daxor's 3-Year Dividend Growth Rate falls into.

Daxor 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Daxor (NAS:DXR) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Daxor's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2023 )	/	EPS without NRI (Q: Dec. 2023 )
	=	0	/	0.69
	=	0.00

During the past 13 years, the highest Dividend Payout Ratio of Daxor was 0.09. The lowest was 0.09. And the median was 0.09.

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

During the past 13 years, the highest Dividend Yield of Daxor was 3.63%. The lowest was 0.22%. And the median was 0.50%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Daxor 3-Year Dividend Growth Rate Related Terms>

Daxor (DXR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Daxor Corp (NAS:DXR) » Definitions » 3-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

DX5:Germany

Address

109 Meco Lane, Oak Ridge, TN, USA, 37830

Website

https://www.daxor.com

Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. It develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.

Executives

Robert J Michel	officer: CHIEF FINANCIAL OFFICER	C/O ASTA FUNDING, INC., 210 SYLVAN AVENUE, ENGLEWOOD CLIFFS NJ 07632
Michael Richard Feldschuh	director	71 GRAND STREET #2, NEW YORK NY 10013
Joy S. Goudie	director	350 FIFTH AVENUE, SUITE 4740, NEW YORK NY 10118
Caleb Desrosiers	director	DAXOR CORPORATION, 109 MECO LANE, OAK RIDGE TN 37830
Henry D. Cremisi	director	350 FIFTH AVENUE, SUITE 4740, NEW YORK NY 10118
Edward Feuer	director	2 WALL STREET, 10TH FLOOR, NEW YORK NY 10005
Soren Thompson	officer: V.P./BUSINESS DEVELOPMENT	180 CENTRAL PARK SOUTH, APT. 805, NEW YORK NY 10019
Jonathan Adam Feldschuh	director, officer: CHIEF SCIENTIFIC OFFICER	DAXOR CORPORATION, 350 5TH AVENUE, SUITE 4740, NEW YORK NY 10118
Joseph Feldschuh	officer: President	615 W. 252ND STREET, BRONX NY 10471
Estate Of Joseph Feldschuh	other: FOUNDER	350 FIFTH AVENUE, SUITE 4740, NEW YORK NY 10118
Diane Marie Meegan	officer: Corporate Secretary	259 NEW YORK AVENUE, JERSEY CITY NJ 07307
Bernhard Saxe	director	6805 WILD ROSE COURT, SPRINGFIELD VA 25152
Robert Willens	director	200 EAST 74TH ST APT 18C, NEW YORK NY 10021
Philip Nordan Hudson	director	P.O. BOX 160892, SAN ANTONIO TX 78280-3092
Everis Engstrom	officer: Vice President	3244 BLACK FOX ROAD, WASHBURN TN 37888